Poseida Therapeutics, Inc.

The momentum for this stock is not very good. Poseida Therapeutics, Inc. is not a good value stock. Poseida Therapeutics, Inc. is not very popular among insiders. Poseida Therapeutics, Inc. is a mediocre stock to choose.
Log in to see more information.
PSTX Fundamental Data by TradingView

News

Poseida Therapeutics: An Underappreciated Company Continuing To Shape Up Well In 2024
Poseida Therapeutics: An Underappreciated Company Continuing To Shape Up Well In 2024

Seeking Alpha - Long Ideas Poseida Therapeutics: An Underappreciated Company Continuing To Shape Up Well In 2024...\n more…

12,000 Shares in Poseida Therapeutics, Inc. (NASDAQ:PSTX) Bought by Rothschild Investment LLC
12,000 Shares in Poseida Therapeutics, Inc. (NASDAQ:PSTX) Bought by Rothschild Investment LLC

Zolmax Rothschild Investment LLC purchased a new stake in Poseida Therapeutics, Inc. (NASDAQ:PSTX - Free Report) in the 2nd quarter, according to the company in its most recent Form 13F filing with the...\n more…

Poseida Therapeutics to Present New Clinical Data from Phase 1 Study of Allogeneic CAR-T P-BCMA-ALLO1 in Patients with Relapsed/Refractory Multiple Myeloma at 21st International Myeloma Socie
Poseida Therapeutics to Present New Clinical Data from Phase 1 Study of Allogeneic CAR-T P-BCMA-ALLO1 in Patients with Relapsed/Refractory Multiple Myeloma at 21st International Myeloma Socie

PR Newswire Poseida Therapeutics to Present New Clinical Data from Phase 1 Study of Allogeneic CAR-T P-BCMA-ALLO1 in Patients with Relapsed/Refractory Multiple Myeloma at 21st International Myeloma Society...\n more…

Poseida Therapeutics Presents New Case Study Demonstrating Reactivation of CAR-T Therapy with a T-Cell Engager in a Patient with Relapsed Multiple Myeloma
Poseida Therapeutics Presents New Case Study Demonstrating Reactivation of CAR-T Therapy with a T-Cell Engager in a Patient with Relapsed Multiple Myeloma

PR Newswire Poseida Therapeutics Presents New Case Study Demonstrating Reactivation of CAR-T Therapy with a T-Cell Engager in a Patient with Relapsed Multiple Myeloma Poseida Therapeutics Presents New Case Study...\n more…

Poseida Therapeutics to Present at Upcoming Investor Conferences
Poseida Therapeutics to Present at Upcoming Investor Conferences

PR Newswire Poseida Therapeutics to Present at Upcoming Investor Conferences Poseida Therapeutics to Present at Upcoming Investor Conferences PR Newswire SAN DIEGO, Aug. 29, 2024 SAN DIEGO, Aug. 29, 2024...\n more…

Ablynx (OTCMKTS:ABLYF) & Poseida Therapeutics (NASDAQ:PSTX) Head-To-Head Analysis
Ablynx (OTCMKTS:ABLYF) & Poseida Therapeutics (NASDAQ:PSTX) Head-To-Head Analysis

Zolmax Ablynx (OTCMKTS:ABLYF - Get Free Report) and Poseida Therapeutics (NASDAQ:PSTX - Get Free Report) are both medical companies, but which is the superior investment? We will compare the two companies...\n more…